bpc-157 type 1 diabetes Multifunctionality and Possible Medical Application of the BPC 157 Peptide—Literature and Patent Review BPC-157 | Reviews, Clinical Trials,

[1] [2] Tirzepatide is not indicated for type 1 diabetes and should not be used in combination with other GLP-1 receptor agonists or DPP-4 inhibitors

In other words, lots of different or pleiotropic effects

However, because the oral bioavailability of standard BPC-157 is limited, it is often delivered via subcutaneous injection

Like all weight loss management programs, they will take time and will have to be completed alongside a healthy diet and regular exercise

Patients who understand that the GH-IGF-1 cycle operates on a 4 to 8 week minimum timeline, and that cumulative results build over 3 to 6 months of consistent protocol adherence, are the ones who complete a full cycle and achieve meaningful body composition change